ShockWave Medical (SWAV)
(Delayed Data from NSDQ)
$328.99 USD
+0.12 (0.04%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $329.08 +0.09 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Company Summary
ShockWave Medical is a medical device company committed to developing and commercializing products created to change the way calcified cardiovascular disease is treated. The company aims to set a new standard of care for medical device treatment of atherosclerotic cardiovascular disease (atherosclerosis) through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, referred to as intravascular lithotripsy by the company. ShockWave Medical’s IVL system supports its IVL technology and is a minimally invasive, simple, and safe way to substantially enhance patient outcomes. The company caters to interventional ...
Company Summary
ShockWave Medical is a medical device company committed to developing and commercializing products created to change the way calcified cardiovascular disease is treated. The company aims to set a new standard of care for medical device treatment of atherosclerotic cardiovascular disease (atherosclerosis) through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, referred to as intravascular lithotripsy by the company. ShockWave Medical’s IVL system supports its IVL technology and is a minimally invasive, simple, and safe way to substantially enhance patient outcomes. The company caters to interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers and distributors.
ShockWave Medical’s IVL catheters are cleared or approved for use in some countries, and development programs are in progress to extend indications and geographies. Coming to the company’s products, its ShockWaveM5 IVL catheter is a five-emitter catheter for utilization in its IVL System in “medium” vessels for treating above-the-knee peripheral artery disease (PAD). In April 2018, the M5 catheter received its CE mark. The FDA cleared it in July 2018.
The company’s S4 IVL catheter is a four-emitter catheter for utilization in its IVL System in small vessels for treating below-the-knee (BTK) PAD. In August 2019, the second version of the company’s S4 catheter was cleared by the FDA and the S4 catheter is CE-marked. When it comes to the treatment of coronary artery disease (CAD), the company’s C2 IVL catheter — a two-emitter catheter in its IVL system is used. In June 2018, the C2 catheter received a CE mark. Meanwhile, in August 2019, its C2 catheters received Breakthrough Device Designation from the FDA. In August 2020, ShockWave Medical submitted an application to the FDA for U.S. pre-market approval of its C2 catheters, which the FDA approved in February 2021.
2023 at a Glance
In 2023, earnings per share came in at $3.85, compared with $5.70 per share. Full-year 2023 revenue was $730.2 million, up 49% from the previous year.
General Information
ShockWave Medical, Inc
5403 Betsy Ross Drive
Santa Clara, CA 95054
Phone: 510-279-4262
Fax: NA
Web: http://www.shockwavemedical.com
Email: investors@shockwavemedical.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.04 |
Current Year EPS Consensus Estimate | 4.94 |
Estimated Long-Term EPS Growth Rate | 27.20 |
Exp Earnings Date | 5/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 328.87 |
52 Week High | 331.58 |
52 Week Low | 157.00 |
Beta | 0.92 |
20 Day Moving Average | 2,020,745.38 |
Target Price Consensus | 306.70 |
4 Week | 1.94 |
12 Week | 45.36 |
YTD | 72.58 |
4 Week | 5.50 |
12 Week | 38.88 |
YTD | 62.31 |
Shares Outstanding (millions) | 37.40 |
Market Capitalization (millions) | 12,298.69 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 66.57 |
Trailing 12 Months | 84.98 |
PEG Ratio | 2.44 |
vs. Previous Year | -68.73% |
vs. Previous Quarter | 26.09% |
vs. Previous Year | 40.93% |
vs. Previous Quarter | 9.12% |
Price/Book | 18.15 |
Price/Cash Flow | 76.25 |
Price / Sales | 16.84 |
3/31/24 | NA |
12/31/23 | 23.97 |
9/30/23 | 42.41 |
3/31/24 | NA |
12/31/23 | 12.78 |
9/30/23 | 26.44 |
3/31/24 | NA |
12/31/23 | 11.76 |
9/30/23 | 14.43 |
3/31/24 | NA |
12/31/23 | 10.73 |
9/30/23 | 13.19 |
3/31/24 | NA |
12/31/23 | 20.17 |
9/30/23 | 36.33 |
3/31/24 | NA |
12/31/23 | 20.17 |
9/30/23 | 36.33 |
3/31/24 | NA |
12/31/23 | 23.87 |
9/30/23 | 24.35 |
3/31/24 | NA |
12/31/23 | 18.12 |
9/30/23 | 16.36 |
3/31/24 | NA |
12/31/23 | 1.00 |
9/30/23 | 1.01 |
3/31/24 | NA |
12/31/23 | 1.09 |
9/30/23 | 1.22 |
3/31/24 | NA |
12/31/23 | 52.26 |
9/30/23 | 54.87 |